Published in J Vis Exp on November 11, 2014
Engineering enhanced protein disaggregases for neurodegenerative disease. Prion (2015) 0.96
Disparate Mutations Confer Therapeutic Gain of Hsp104 Function. ACS Chem Biol (2015) 0.79
Mechanistic Insights into Hsp104 Potentiation. J Biol Chem (2016) 0.78
Engineering therapeutic protein disaggregases. Mol Biol Cell (2016) 0.76
Protein-Remodeling Factors As Potential Therapeutics for Neurodegenerative Disease. Front Neurosci (2017) 0.75
5-Fluoroorotic acid as a selective agent in yeast molecular genetics. Methods Enzymol (1987) 17.67
Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science (2006) 7.72
High-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method. Nat Protoc (2007) 5.62
Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature (2010) 5.26
Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science (2003) 4.45
Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med (2004) 3.93
Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet (2009) 3.59
A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc Natl Acad Sci U S A (2008) 3.46
A suite of Gateway cloning vectors for high-throughput genetic analysis in Saccharomyces cerevisiae. Yeast (2007) 3.30
Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLoS Biol (2011) 2.70
Chaperone machines for protein folding, unfolding and disaggregation. Nat Rev Mol Cell Biol (2013) 2.24
Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis Model Mech (2009) 2.16
Operational plasticity enables hsp104 to disaggregate diverse amyloid and nonamyloid clients. Cell (2012) 2.03
A yeast model of FUS/TLS-dependent cytotoxicity. PLoS Biol (2011) 1.95
Yeast reveal a "druggable" Rsp5/Nedd4 network that ameliorates α-synuclein toxicity in neurons. Science (2013) 1.85
Therapeutic modulation of eIF2α phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat Genet (2013) 1.63
Hsp104: a weapon to combat diverse neurodegenerative disorders. Neurosignals (2007) 1.40
Applying Hsp104 to protein-misfolding disorders. Biochem Cell Biol (2010) 1.18
Stress, aging, and neurodegenerative disease. N Engl J Med (2006) 1.18
Creating random mutagenesis libraries by megaprimer PCR of whole plasmid (MEGAWHOP). Methods Mol Biol (2003) 1.16
Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events. Cell (2014) 1.13
Different 8-hydroxyquinolines protect models of TDP-43 protein, α-synuclein, and polyglutamine proteotoxicity through distinct mechanisms. J Biol Chem (2011) 1.04
TDP-43 toxicity in yeast. Methods (2010) 0.91
Protein engineering for therapeutics, part B. Preface. Methods Enzymol (2012) 0.81